Defining a memory checkpoint for CD4 T cells

定义 CD4 T 细胞的记忆检查点

基本信息

  • 批准号:
    8938979
  • 负责人:
  • 金额:
    $ 41.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-06-01 至 2020-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Infection with a live pathogen generates an impressive T cell effector response that that clears virus and results in generation of memory CD4 and CD8 T cells as well long-lived B cells that make antibody to pathogen. Each of these arms of the immune response can provide potent protection against re-infection, but the most powerful immunity occurs when all components are present. Vaccine-induced immunological memory can also be a powerful tool to fight infectious diseases. Most attention has focused on inducing neutralizing antibody with much less attention given to achieving T cell immunity, even though B cell immunity can be readily thwarted by viruses and other pathogens that present rapidly changing surface proteins recognized by B cells. Many current vaccines do a poor job of eliciting CD4 T cell immunity and thus are less effective than they could be. We have analyzed the process in which CD4 effectors that are highly susceptible to apoptotic death become resting, long-lived memory CD4 T cells. We find that after influenza A virus infection, generation of CD4 memory cells is dependent on effectors recognizing the pathogen at the peak of the response. The effectors must produce the growth and survival cytokine, IL-2. This recognition of the pathogen leads to short and long- term survival of a small cohort of effectors so they can transition to memory and be maintained for months or years. Without these components little or no CD4 memory develops. Thus this step acts as a "Memory Checkpoint". We propose that most memory CD4 T cells require these events to become memory and that the pathogen provides not only the antigen the CD4 T cells must recognize, but also supplies "danger signals" to directly activates the cells that the CD4 T cells interact with in an effective way. We also propose that the interaction of CD4 T cells with pathogen-activated antigen-presenting cells provides unique signals that drive the transition to memory that contrasts to further effector differentiation. We will test these hypotheses and define the mechanistic pathways involved. In so doing we expect to discover key requirements for CD4 memory generation that will inform development of more effective vaccines to achieve CD4 memory.
 描述(申请人提供):感染活的病原体会产生令人印象深刻的T细胞效应反应,这种反应可以清除病毒,并导致产生记忆的CD4和CD8T细胞以及产生抗病原体抗体的长寿B细胞。免疫反应的每一个手臂都可以提供有效的保护,防止再次感染,但最强大的免疫力发生在所有组件都存在的情况下。疫苗诱导的免疫记忆也可以成为对抗传染病的有力工具。大多数人的注意力集中在诱导中和抗体上,而对获得T细胞免疫的关注要少得多,尽管B细胞免疫很容易被病毒和其他病原体挫败,这些病毒和其他病原体呈现出快速变化的B细胞识别的表面蛋白。许多目前的疫苗在激发CD4T细胞免疫方面做得很差,因此效果不如它们应有的效果。我们已经分析了高度易受凋亡死亡影响的CD4效应器成为静止的、长期记忆的CD4T细胞的过程。我们发现,在甲型流感病毒感染后,CD4记忆细胞的产生依赖于在反应高峰期识别病原体的效应器。效应器必须产生生长和生存细胞因子IL-2。这种对病原体的识别导致了一小群效应者的短期和长期存活,这样他们就可以过渡到记忆中,并维持数月或数年。如果没有这些成分,很少或根本没有CD4记忆的形成。因此,此步骤相当于一个“内存检查点”。我们认为,大多数记忆的CD4T细胞需要这些事件才能成为记忆,病原体不仅提供CD4T细胞必须识别的抗原,而且还提供“危险信号”,以有效地直接激活与CD4T细胞相互作用的细胞。我们还提出,CD4T细胞与病原体激活的抗原提呈细胞的相互作用提供了独特的信号,推动了与进一步的效应器分化相反的向记忆的转变。我们将测试这些假设,并定义所涉及的机制路径。在这样做的过程中,我们希望发现产生CD4记忆的关键要求,这将有助于开发更有效的疫苗来实现CD4记忆。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUSAN L SWAIN其他文献

SUSAN L SWAIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUSAN L SWAIN', 18)}}的其他基金

Harnessing Age-Associated B cells for a Universal Influenza Vaccine for the Aged
利用与年龄相关的 B 细胞开发针对老年人的通用流感疫苗
  • 批准号:
    10573680
  • 财政年份:
    2022
  • 资助金额:
    $ 41.88万
  • 项目类别:
Age-Associated B Cells Specialized for Immunity to Pathogens?
与年龄相关的 B 细胞专门针对病原体具有免疫能力?
  • 批准号:
    10218497
  • 财政年份:
    2021
  • 资助金额:
    $ 41.88万
  • 项目类别:
Age-Associated B Cells Specialized for Immunity to Pathogens?
与年龄相关的 B 细胞专门针对病原体具有免疫能力?
  • 批准号:
    10401919
  • 财政年份:
    2021
  • 资助金额:
    $ 41.88万
  • 项目类别:
Impact of TcR Signal Strength at the Effector Checkpoint on Protective CD4 T Cell Immunity to Influenza Virus
效应器检查点 TcR 信号强度对保护性 CD4 T 细胞对流感病毒免疫的影响
  • 批准号:
    10187518
  • 财政年份:
    2020
  • 资助金额:
    $ 41.88万
  • 项目类别:
Impact of TcR Signal Strength at the Effector Checkpoint on Protective CD4 T Cell Immunity to Influenza Virus
效应器检查点 TcR 信号强度对保护性 CD4 T 细胞对流感病毒免疫的影响
  • 批准号:
    10027026
  • 财政年份:
    2020
  • 资助金额:
    $ 41.88万
  • 项目类别:
Maintaining Robust T Cell Immunity For Broad Protection Against Influenza
维持强大的 T 细胞免疫力以广泛预防流感
  • 批准号:
    9806329
  • 财政年份:
    2019
  • 资助金额:
    $ 41.88万
  • 项目类别:
VACCINE STRATEGIES TO CIRCUMVENT AGE-ASSOCIATED IMMUNE DEFECTS
规避年龄相关免疫缺陷的疫苗策略
  • 批准号:
    9762805
  • 财政年份:
    2018
  • 资助金额:
    $ 41.88万
  • 项目类别:
Defining a memory checkpoint for CD4 T cells
定义 CD4 T 细胞的记忆检查点
  • 批准号:
    9064064
  • 财政年份:
    2015
  • 资助金额:
    $ 41.88万
  • 项目类别:
Generation and persistence of CD4 memory subsets
CD4 内存子集的生成和持久化
  • 批准号:
    8316250
  • 财政年份:
    2011
  • 资助金额:
    $ 41.88万
  • 项目类别:
CD4 effector contraction in influenza
流感中 CD4 效应器收缩
  • 批准号:
    8300101
  • 财政年份:
    2011
  • 资助金额:
    $ 41.88万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 41.88万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 41.88万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 41.88万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 41.88万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 41.88万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 41.88万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 41.88万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 41.88万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了